Key regions: France, India, United Kingdom, South Korea, Japan
Belarus, a country situated in Eastern Europe, has been experiencing a steady growth in the Multiple Sclerosis Drugs market.
Customer preferences: Patients suffering from Multiple Sclerosis in Belarus prefer drugs that are effective and affordable. They also prefer drugs that have fewer side effects and can be easily administered.
Trends in the market: One of the major trends in the Multiple Sclerosis Drugs market in Belarus is the increasing demand for disease-modifying therapies (DMTs). DMTs have been proven to be effective in slowing down the progression of the disease and reducing the frequency and severity of relapses. Another trend is the increasing use of oral medications. Oral medications are more convenient for patients as they do not require injections or infusions.
Local special circumstances: Belarus has a centralized healthcare system, and the government plays a significant role in regulating the pharmaceutical industry. The government has been working to improve access to healthcare for its citizens, and this has led to an increase in the demand for Multiple Sclerosis Drugs. Additionally, the country has a high prevalence of Multiple Sclerosis, which has contributed to the growth of the market.
Underlying macroeconomic factors: Belarus has a stable economy, and the government has been working to attract foreign investment in the pharmaceutical industry. The country has a well-educated workforce, and this has helped to drive innovation in the industry. The government has also been working to improve the regulatory environment for pharmaceutical companies, which has led to an increase in the number of drugs available in the market. In conclusion, the Multiple Sclerosis Drugs market in Belarus is experiencing steady growth due to the increasing demand for DMTs, the use of oral medications, the centralized healthcare system, the high prevalence of Multiple Sclerosis, the stable economy, the well-educated workforce, and the government's efforts to improve the regulatory environment.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
